Palatin fortifies balance sheet to fuel next-generation obesity drug trials
Share
Palatin Technologies (NYSE:PTN) reported its fiscal second-quarter 2026 results on Tuesday, marking a critical operational pivot as the biopharmaceutical firm clears financial hurdles and prepares to enter the highly competitive clinical landscape for weight-loss therapies.
The Cranbury, New Jersey-based developer, which specializes in melanocortin receptor system modulation, ended the period on December 31, 2025, with a significantly bolstered balance sheet.
Following an $18.2 million public offering, Palatin’s cash position climbed to $14.5 million.
Management confirmed this capital provides a cash runway extending beyond March 31, 2027, effectively removing the near-term financing overhang that had previously pressured the stock.
The liquidity boost coincides with Palatin successfully regaining its listing compliance on the NYSE American exchange.
This milestone restores crucial market visibility and institutional access as the company prepares to initiate human trials for its obesity programs later this calendar year.
The centerpiece of Palatin’s 2026 strategy is its Melanocortin-4 Receptor (MC4R) portfolio, which aims to provide a differentiated therapeutic mechanism from the dominant GLP-1 incretin therapies currently commanding the market.
The company remains on track to file an Investigational New Drug application and initiate a Phase 1 study for PL7737, an oral small-molecule candidate, in the first half of 2026.
PL7737 is being positioned as a potential treatment for both general and rare forms of obesity, including hypothalamic obesity.
Simultaneously, Palatin is advancing long-acting peptide candidates designed for once-weekly subcutaneous dosing.
The company is targeting IND filings and Phase 1 trial initiations for these peptide candidates in the second half of 2026.
Palatin’s balance sheet was further supported by strategic global collaborations and licensing execution.
The company recognized a €2 million upfront payment from Boehringer Ingelheim as part of an ongoing partnership.
Additionally, the company secured a $3.8 million payment stemming from a sublicensing agreement for PL9643.
